

# Peter S Linsley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6683144/publications.pdf>

Version: 2024-02-01

32  
papers

5,931  
citations

304743

22  
h-index

434195

31  
g-index

34  
all docs

34  
docs citations

34  
times ranked

9630  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. <i>Genome Biology</i> , 2015, 16, 278.           | 8.8  | 2,047     |
| 2  | Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. <i>Nature</i> , 1996, 381, 434-438.   | 27.8 | 1,430     |
| 3  | An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2019, 381, 603-613.   | 27.0 | 584       |
| 4  | A phenotypically and functionally distinct human T <sub>H</sub> 2 cell subpopulation is associated with allergic disorders. <i>Science Translational Medicine</i> , 2017, 9, .                     | 12.4 | 291       |
| 5  | Copy Number Loss of the Interferon Gene Cluster in Melanomas Is Linked to Reduced T Cell Infiltrate and Poor Patient Prognosis. <i>PLoS ONE</i> , 2014, 9, e109760.                                | 2.5  | 192       |
| 6  | Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. <i>Science Immunology</i> , 2016, 1, .   | 11.9 | 169       |
| 7  | Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. <i>Nature Communications</i> , 2020, 11, 219.                            | 12.8 | 167       |
| 8  | The clinical utility of inhibiting CD28-mediated costimulation. <i>Immunological Reviews</i> , 2009, 229, 307-321.   | 6.0  | 148       |
| 9  | Autoreactive CD8+ T cell exhaustion distinguishes subjects with slow type 1 diabetes progression. <i>Journal of Clinical Investigation</i> , 2019, 130, 480-490.                                   | 8.2  | 99        |
| 10 | Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. <i>JCI Insight</i> , 2018, 3, .   | 5.0  | 85        |
| 11 | Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. <i>Diabetologia</i> , 2019, 62, 655-664.  | 6.3  | 74        |
| 12 | Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes. <i>Cellular Immunology</i> , 2017, 319, 3-9.  | 3.0  | 72        |
| 13 | Single-Cell RNA Sequencing Reveals Expanded Clones of Islet Antigen-Reactive CD4+ T Cells in Peripheral Blood of Subjects with Type 1 Diabetes. <i>Journal of Immunology</i> , 2017, 199, 323-335. | 0.8  | 62        |
| 14 | Controlled Human Malaria Infection Leads to Long-Lasting Changes in Innate and Innate-like Lymphocyte Populations. <i>Journal of Immunology</i> , 2017, 199, 107-118.                              | 0.8  | 45        |
| 15 | The human tissue-resident CCR5 <sup>+</sup> T cell compartment maintains protective and functional properties during inflammation. <i>Science Translational Medicine</i> , 2019, 11, .             | 12.4 | 41        |
| 16 | Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes. <i>Genes and Immunity</i> , 2019, 20, 293-307.               | 4.1  | 41        |
| 17 | Renal Cell Carcinoma (RCC) Tumors Display Large Expansion of Double Positive (DP) CD4+CD8+ T Cells With Expression of Exhaustion Markers. <i>Frontiers in Immunology</i> , 2018, 9, 2728.          | 4.8  | 39        |
| 18 | B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes. <i>JCI Insight</i> , 2019, 4, .  | 5.0  | 39        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Cell type-specific immune phenotypes predict loss of insulin secretion in new-onset type 1 diabetes. JCI Insight, 2019, 4, .  | 5.0  | 38        |
| 20 | Exhausted-like CD8+ T cell phenotypes linked to C-peptide preservation in alefacept-treated T1D subjects. JCI Insight, 2021, 6, .   | 5.0  | 37        |
| 21 | Pcsk9 Deletion Promotes Murine Nonalcoholic Steatohepatitis and Hepatic Carcinogenesis: Role of Cholesterol. Hepatology Communications, 2022, 6, 780-794.                               | 4.3  | 28        |
| 22 | IRF5 genetic risk variants drive myeloid-specific IRF5 hyperactivation and presymptomatic SLE. JCI Insight, 2020, 5, .  | 5.0  | 27        |
| 23 | Innate immune stimulation of whole blood reveals IFN-1 hyper-responsiveness in type 1 diabetes. Diabetologia, 2020, 63, 1576-1587.  | 6.3  | 26        |
| 24 | Enforcing the checkpoints. Current Opinion in Endocrinology, Diabetes and Obesity, 2019, 26, 213-218.   | 2.3  | 25        |
| 25 | The Relationship of Immune Cell Signatures to Patient Survival Varies within and between Tumor Types. PLoS ONE, 2015, 10, e0138726.   | 2.5  | 24        |
| 26 | Inflammatory Cytokines Induce Sustained CTLA-4 Cell Surface Expression on Human MAIT Cells. ImmunoHorizons, 2020, 4, 14-22.   | 1.8  | 24        |
| 27 | Uncovering Pathways to Personalized Therapies in Type 1 Diabetes. Diabetes, 2021, 70, 831-841.  | 0.6  | 20        |
| 28 | Deep immune phenotyping reveals similarities between aging, Down syndrome, and autoimmunity. Science Translational Medicine, 2022, 14, eabi4888.  | 12.4 | 20        |
| 29 | A composite immune signature parallels disease progression across T1D subjects. JCI Insight, 2019, 4, .   | 5.0  | 15        |
| 30 | Autoreactive T cell receptors with shared germline-like $\hat{\pm}$ chains in type 1 diabetes. JCI Insight, 2021, 6, .  | 5.0  | 14        |
| 31 | Pillars article: long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996. 381: 434-438. 1996. Journal of Immunology, 2011, 186, 2693-7. | 0.8  | 8         |
| 32 | IL-6-Driven pSTAT1 Response Is Linked to T Cell Features Implicated in Early Immune Dysregulation. Frontiers in Immunology, 0, 13, .  | 4.8  | 0         |